WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 1, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced that it has filed a preliminary prospectus supplement to its effective shelf registration statement with the Securities and Exchange Commission relating to a proposed underwritten public offering of six million shares of its common stock. The underwriters will be granted an over-allotment option for an additional 900,000 shares of common stock. All of the shares are being sold by OXiGENE.
